This, therefore, raises the exciting prospect of combining iNOS inhibitors (or other strategies that target iNOS+ MDSCs) with IFNγ-based cancer therapies, which may show potentiation by removing the pro-tumoural aspect of IFNγ while preserving the anti-tumoural functions. The gene discussed is NOS2; the disease is cancer.